Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial

BACKGROUND: First-line rituximab therapy together with chemotherapy is the standard care for patients with advanced follicular B-cell lymphoma, as rituximab together with chemotherapy prolongs progression-free and overall survival (Herold et al. 2007; Marcus et al. 2005). However, as not all patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Budau, Laura, Wilhelm, Christian, Moll, Roland, Jäkel, Jörg, Hirt, Carsten, Dölken, Gottfried, Maschmeyer, Georg, Neubauer, Ellen, Strauch, Konstantin, Burchert, Andreas, Herold, Michael, Neubauer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658576/
https://www.ncbi.nlm.nih.gov/pubmed/31273513
http://dx.doi.org/10.1007/s00432-019-02961-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658576/
https://www.ncbi.nlm.nih.gov/pubmed/31273513
http://dx.doi.org/10.1007/s00432-019-02961-9

Ejemplares similares